Alexandria Real Estate Equities (ARE) Declines -13.8% Over 30 Days After Analyst Downgrades
Key Takeaways
- Alexandria Real Estate Equities (ARE) fell roughly 13.8% over the last 30 days, moving from $49.93 to $43.02.
- The decline followed several analyst downgrades and reduced price targets linked to ongoing challenges in life science real estate.
- Over the past quarter, the stock has also weakened, continuing a broader multi-year downtrend.
- Second-quarter 2026 results included a net loss, lower occupancy, and reduced same-property net operating income.
- Higher interest rates and increased leverage are pressuring the REIT's valuation even with a dividend yield near 6%.
Company Overview: Alexandria Real Estate Equities (ARE)
Alexandria Real Estate Equities, Inc. is an S&P 500 real estate investment trust that helped establish the life science real estate sector. Founded in 1994, the company owns and develops collaborative “Megacampus” properties in major innovation hubs such as Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, the Research Triangle, and New York City. It provides specialized laboratory and office space to life science, agtech, and technology tenants, primarily under triple-net leases.
Its strengths include a portfolio of mission-critical assets near leading academic and medical centers, long-term tenant relationships, and a venture capital arm that connects it to emerging biotech firms. Investors track ARE for its exposure to long-term life science demand, dividend income, and net asset value, though the shares have faced pressure as the sector addresses supply-demand imbalances.
ARE Stock Performance Over the Last 30 Days and Quarter
From a close of $49.93 on September 25, 2026, to $43.02 on October 23, 2026, ARE dropped about 13.8%. Several sharp declines in October coincided with worsening analyst views.
The quarterly trend shows a similar low-teens percentage drop, extending a longer-term decline from the 52-week high. The recent move appears to be an acceleration of that established downtrend rather than a standalone event.
Factors Behind the Recent 30-Day Move
A series of analyst actions stood out as the clearest trigger. Baird lowered its rating to Neutral from Outperform and cut its target to $46 from $67. BMO Capital reduced its target to $41 from $48. Citigroup trimmed its target to $42 from $52, Cantor Fitzgerald moved to $43 from $60, and RBC Capital lowered its target to $50 from $60.
These changes reflect deeper concerns. Second-quarter 2026 results showed a net loss, declining occupancy, and softer same-property net operating income. Higher interest rates have increased the cost of capital for a REIT with elevated leverage, while the life science sector works through excess lab supply and slower biotech funding. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Quarterly Drivers and Sector Context
Over the quarter, the main story has been the ongoing supply-demand imbalance in key life science markets. New space delivered in recent years continues to be absorbed, limiting occupancy gains and rental growth even in top clusters. Financing costs remain high, and the company’s leverage has increased relative to peers, drawing more balance-sheet attention.
While Alexandria’s high-quality campuses are often seen as likely beneficiaries of a “flight to quality” once new supply slows, that improvement has not yet appeared consistently in results. Weakening same-property metrics and cautious analyst positioning have kept the shares under pressure.
Key Items to Watch Going Forward
Attention will turn to the next earnings report and management updates on leasing, occupancy, and same-property net operating income. The path of interest rates matters greatly, since lower borrowing costs could support both REIT valuations and biotech funding. Further analyst target changes, supply trends in life science markets, and the pace of venture capital recovery will also influence direction. These longer-term elements, rather than daily price moves, are likely to matter most in the quarters ahead.
Using Tickeron’s AI Tools for Research
I often turn to Tickeron’s Trending AI Robots page when looking for systematic signals across many tickers. The section highlights top-performing AI-driven strategies with different timeframes and approaches, which can complement fundamental work on names like ARE. Reviewing these options helps surface data-driven ideas that align with my own analysis process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARE sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ARE moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARE as a result. In 46 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
ARE moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARE crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Aroon Indicator for ARE entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARE's RSI Indicator exited the oversold zone, 17 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 52%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 56 cases where ARE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for ARE just turned positive on October 23, 2026. Looking at past instances where ARE's MACD turned positive, the stock continued to rise in 22 of 34 cases over the following month. The odds of a continued upward trend are 65%.
ARE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.538) is normal, around the industry mean (0.873). P/E Ratio (102.987) is within average values for comparable stocks, (201.021). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (0.666). Dividend Yield (0.072) settles around the average of (0.163) among similar stocks. ARE's P/S Ratio (7.435) is very high in comparison to the industry average of (2.856).
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ARE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a real estate investment trust
Industry REITOffice
Advertisement